UnknownNot Applicable

Fetal Cell Analysis From Maternal Blood

Italy1,500 participantsStarted 2021-11-22

Plain-language summary

The aim of this clinical study is the evaluation of clinical performance of a cell-based non-invasive test technology for fetal aneuploidies and segmental imbalances detection in a high-risk pregnancies population.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant has a viable singleton or twin pregnancy * Women who have already been selected by their treating physician to undergo an invasive fetal diagnostic procedure * Participant is at least 18 years old and can provide informed consent Exclusion Criteria: * Unable to provide informed consent * Prenatal diagnosis of clinical Chorioamnionitis * Intake of drugs or exposure to teratogenic agents * Infections that carry a risk of vertical transmission * Known maternal viral diseases: HIV and HCV, HBV

What they're measuring

Fetal chromosomal abnormalities detection in circulating fetal cells,

Timeframe: 2 year

Trial details

NCT IDNCT05671744

SponsorMenarini Biomarkers Singapore

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-09

Contact for this trial

Chiara Bolognesi

+39 051 9944165 cbolognesi@siliconbiosystems.com

View on ClinicalTrials.gov More Prenatal Screening trials